The current portfolio of the firm consists of 157 products which have been certified for the distribution in the market of the United States and 58 Abbreviated New Drug Application’s pending approval with the United States Food and Drug Administration.
There is an increase in the shares of the Glenmark Pharmaceuticals in early trade on the 28th of July where the firm received approval of the United States Food and Drug Administration for two products; Simvastatin & Ezetimibe tablets.
The branch in the United States of America of Glenmark Pharmaceuticals Inc. has been granted approval by the United States Food & Drug Administration for the two tablets, 10 milligram/10 milligram, 10 milligram/20 milligram, 10 milligram/40 milligram, and 10 milligram/80 milligram, a common version of Vytorin 1 Tablets, 10 milligram/10 milligram, 10 milligram/20 milligram, 10 milligram/40 milligram, and 10 milligram/80 milligram of MSD International GmbH, as per release of BSE.
Apart from these internal filings, Glenmark continues the identification and exploration of external development associations to complement and accelerate the growth of its current pipeline and portfolio.
About the company
Glenmark was discovered with a vision to appear as a pioneering integrated research-based, global pharma firm. Over several years, they have developed ourselves as a foremost player in the discovery of new molecules both NCEs and NBEs.They have numerous molecules in various stages of pre-clinical & clinical development and are mainly focused on the areas of Dermatology, Oncology & Respiratory.
Their exclusive generics business has a noteworthy presence in markets across emerging economies inclusive of India.
The generics business services the requirements of established markets like the United States and Western Europe. Our API business vends products in more than 80 countries including the United States, various countries in South America, the European Union, and India.